CBD AND ALZHEIMER'S DISEASE
Cannabis and Neuropsychiatric Disorders: An
Updated Review.
Chayasirisobhon S.
Acta Neurol Taiwan. 2019 Jun 15;28(2):27-39. Review. PMID:31867704
Effects of cannabidiol (CBD) in neuropsychiatric
disorders: A review of pre-clinical and clinical findings.
Elsaid S, Kloiber S, Le Foll B.
Prog Mol Biol Transl Sci. 2019;167:25-75. doi:
10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28. PMID:31601406
Cannabis Therapeutics and the Future of Neurology.
Russo EB.
Front Integr Neurosci. 2018 Oct 18;12:51. doi:
10.3389/fnint.2018.00051. eCollection 2018. PMID:30405366
Free PMC Article
Cannabidiol enhances morphine antinociception,
diminishes NMDA-mediated seizures and reduces stroke damage via
the sigma 1 receptor.
Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J,
Sánchez-Blázquez P.
Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.
PMID:30223868
Free PMC Article
GPR3, GPR6, and GPR12 as novel molecular targets:
their biological functions and interaction with cannabidiol.
Laun AS, Shrader SH, Brown KJ, Song ZH.
Acta Pharmacol Sin. 2019 Mar;40(3):300-308. doi:
10.1038/s41401-018-0031-9. Epub 2018 Jun 25. Review. PMID:29941868
Is Cannabidiol a Promising Substance for New Drug
Development? A Review of its Potential Therapeutic Applications.
Noreen N, Muhammad F, Akhtar B, Azam F, Anwar MI.
Crit Rev Eukaryot Gene Expr. 2018;28(1):73-86. doi:
10.1615/CritRevEukaryotGeneExpr.2018021528. Review. PMID:29773016
Review of the neurological benefits of
phytocannabinoids.
Maroon J, Bost J.
Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18.
eCollection 2018. Review. PMID:29770251
Free PMC Article
Prolonged Cannabidiol Treatment Effects on
Hippocampal Subfield Volumes in Current Cannabis Users.
Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH,
Yücel M, Solowij N.
Cannabis Cannabinoid Res. 2018 Apr 1;3(1):94-107. doi:
10.1089/can.2017.0047. eCollection 2018. PMID:29682609
Free PMC Article
Cannabidiol Reverses Deficits in Hippocampal LTP
in a Model of Alzheimer's Disease.
Hughes B, Herron CE.
Neurochem Res. 2019 Mar;44(3):703-713. doi:
10.1007/s11064-018-2513-z. Epub 2018 Mar 24. PMID:29574668
Effects of cannabidiol interactions with
Wnt/β-catenin pathway and PPARγ on oxidative stress and
neuroinflammation in Alzheimer's disease.
Vallée A, Lecarpentier Y, Guillevin R, Vallée JN.
Acta Biochim Biophys Sin (Shanghai). 2017 Oct 1;49(10):853-866. doi:
10.1093/abbs/gmx073. PMID:28981597
GPR3 and GPR6, novel molecular targets for
cannabidiol.
Laun AS, Song ZH.
Biochem Biophys Res Commun. 2017 Aug 12;490(1):17-21. doi:
10.1016/j.bbrc.2017.05.165. Epub 2017 May 29. PMID:28571738
Neurological Aspects of Medical Use of
Cannabidiol.
Mannucci C, Navarra M, Calapai F, Spagnolo EV, Busardò FP, Cas RD,
Ippolito FM, Calapai G.
CNS Neurol Disord Drug Targets. 2017;16(5):541-553. doi:
10.2174/1871527316666170413114210. Review. PMID:28412918
Cannabinoids therapeutic use: what is our current
understanding following the introduction of THC, THC:CBD
oromucosal spray and others?
Maccarrone M, Maldonado R, Casas M, Henze T, Centonze D.
Expert Rev Clin Pharmacol. 2017 Apr;10(4):443-455. doi:
10.1080/17512433.2017.1292849. Epub 2017 Feb 28. Review.
PMID:28276775
In vivo Evidence for Therapeutic Properties
of Cannabidiol (CBD) for Alzheimer's Disease.
Watt G, Karl T.
Front Pharmacol. 2017 Feb 3;8:20. doi: 10.3389/fphar.2017.00020.
eCollection 2017. Review. PMID:28217094
Free PMC Article
Cannabidiol Modulates the Expression of
Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells.
Libro R, Diomede F, Scionti D, Piattelli A, Grassi G, Pollastro F,
Bramanti P, Mazzon E, Trubiani O.
Int J Mol Sci. 2016 Dec 23;18(1). pii: E26. doi:
10.3390/ijms18010026. PMID:28025562
Free PMC Article
A systematic review of the effect of cannabidiol
on cognitive function: Relevance to schizophrenia.
Osborne AL, Solowij N, Weston-Green K.
Neurosci Biobehav Rev. 2017 Jan;72:310-324. doi:
10.1016/j.neubiorev.2016.11.012. Epub 2016 Nov 22. Review.
PMID:27884751
Delineating the Efficacy of a Cannabis-Based
Medicine at Advanced Stages of Dementia in a Murine Model.
Aso E, Andrés-Benito P, Ferrer I.
J Alzheimers Dis. 2016 Oct 4;54(3):903-912. PMID:27567873
Free Article
The therapeutic potential of the phytocannabinoid
cannabidiol for Alzheimer's disease.
Karl T, Garner B, Cheng D.
Behav Pharmacol. 2017 Apr;28(2 and 3-Spec Issue):142-160. doi:
10.1097/FBP.0000000000000247. Review. PMID:27471947
Cannabis-based medicine reduces multiple
pathological processes in AβPP/PS1 mice.
Aso E, Sánchez-Pla A, Vegas-Lozano E, Maldonado R, Ferrer I.
J Alzheimers Dis. 2015;43(3):977-91. doi: 10.3233/JAD-141014.
PMID:25125475
Free Article
Long-term cannabidiol treatment prevents the
development of social recognition memory deficits in Alzheimer's
disease transgenic mice.
Cheng D, Spiro AS, Jenner AM, Garner B, Karl T.
J Alzheimers Dis. 2014;42(4):1383-96. doi: 10.3233/JAD-140921.
PMID:25024347
Chronic cannabidiol treatment improves social and
object recognition in double transgenic APPswe/PS1∆E9 mice.
Cheng D, Low JK, Logge W, Garner B, Karl T.
Psychopharmacology (Berl). 2014 Aug;231(15):3009-17. doi:
10.1007/s00213-014-3478-5. Epub 2014 Mar 1. PMID:24577515
Cannabidiol promotes amyloid precursor protein
ubiquitination and reduction of beta amyloid expression in
SHSY5YAPP+ cells through PPARγ involvement.
Scuderi C, Steardo L, Esposito G.
Phytother Res. 2014 Jul;28(7):1007-13. doi: 10.1002/ptr.5095. Epub
2013 Nov 28. PMID:24288245
Cannabidiol reduces Aβ-induced neuroinflammation
and promotes hippocampal neurogenesis through PPARγ involvement.
Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D,
Cipriano M, Carratù MR, Iuvone T, Steardo L.
PLoS One. 2011;6(12):e28668. doi: 10.1371/journal.pone.0028668. Epub
2011 Dec 5. PMID:22163051
Free PMC Article
Cannabidiol and other cannabinoids reduce
microglial activation in vitro and in vivo: relevance to
Alzheimer's disease.
Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato
N, Cuadrado A, de Ceballos ML.
Mol Pharmacol. 2011 Jun;79(6):964-73. doi: 10.1124/mol.111.071290.
Epub 2011 Feb 24. PMID:21350020
Free PMC Article
Therapeutic Potential of Non-Psychotropic
Cannabidiol in Ischemic Stroke.
Hayakawa K, Mishima K, Fujiwara M.
Pharmaceuticals (Basel). 2010 Jul 8;3(7):2197-2212. Review.
PMID:27713349
Free PMC Article Cannabinoids for the treatment of dementia.
Krishnan S, Cairns R, Howard R.
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007204. doi:
10.1002/14651858.CD007204.pub2. Review. PMID:19370677
Cannabidiol: a promising drug for
neurodegenerative disorders?
Iuvone T, Esposito G, De Filippis D, Scuderi C, Steardo L.
CNS Neurosci Ther. 2009 Winter;15(1):65-75. doi:
10.1111/j.1755-5949.2008.00065.x. Review. PMID:19228180
Free PMC Article
Cannabidiol: from an inactive cannabinoid to a
drug with wide spectrum of action.
Zuardi AW.
Braz J Psychiatry. 2008 Sep;30(3):271-80. Review. PMID:18833429
Free Article
Cannabidiol in vivo blunts beta-amyloid induced
neuroinflammation by suppressing IL-1beta and iNOS expression.
Esposito G, Scuderi C, Savani C, Steardo L Jr, De Filippis D,
Cottone P, Iuvone T, Cuomo V, Steardo L.
Br J Pharmacol. 2007 Aug;151(8):1272-9. Epub 2007 Jun 25.
PMID:17592514
Free PMC Article
Cannabidiol inhibits inducible nitric oxide
synthase protein expression and nitric oxide production in
beta-amyloid stimulated PC12 neurons through p38 MAP kinase and
NF-kappaB involvement.
Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R,
Iuvone T.
Neurosci Lett. 2006 May 15;399(1-2):91-5. Epub 2006 Feb 21.
PMID:16490313